title: A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.
abstract: To gain consensus on the role of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer, a panel of expert oncologists experienced in treating patients with metastatic breast cancer in Italy participated in a Delphi consensus study. The panel reached a full consensus on the efficacy of bevacizumab plus paclitaxel and the clinical meaningfulness of the progression-free survival benefit compared with paclitaxel alone, despite the lack of an overall survival effect in clinical trials. The participants agreed that real-world data support the effectiveness and well-defined safety profile of the regimen. Views on the use of bevacizumab plus paclitaxel in specific patient populations were not unanimous and clinical judgment remains important. Nevertheless, a high level of agreement was reached.
authors.affiliation: Department of Medical & Biological Sciences, University of Udine, Udine, Italy.
authors.forename: Fabio
authors.initials: F
authors.lastname: Puglisi
authors.affiliation: Oncology Unit, Department of Oncology, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy.
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Bisagni
authors.affiliation: Department of Medical Oncology, Vito Fazzi Hospital, Lecce, Italy.
authors.forename: Mariangela
authors.initials: M
authors.lastname: Ciccarese
authors.affiliation: Department of Medical & Biological Sciences, University of Udine, Udine, Italy.
authors.forename: Caterina
authors.initials: C
authors.lastname: Fontanella
authors.affiliation: Medical Oncology Unit, ASL Frosinone, Frosinone, Italy.
authors.forename: Teresa
authors.initials: T
authors.lastname: Gamucci
authors.affiliation: Oncology Unit, Azienda Ospedaliera dei Colli, Naples, Italy.
authors.forename: Luigi
authors.initials: L
authors.lastname: Leo
authors.affiliation: University of Verona, Verona, Italy.
authors.forename: Annamaria
authors.initials: A
authors.lastname: Molino
authors.affiliation: Medical Oncology Unit, ASUR Marche AV2 Fabriano, Fabriano, Italy.
authors.forename: Rosa Rita
authors.initials: RR
authors.lastname: Silva
authors.affiliation: Medical Oncology, Sant'Andrea Hospital, Sapienza University of Rome & IDI-IRCCS, Rome, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Marchetti
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007558:Italy; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000473:pathology*; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D011795:Surveys and Questionnaires
chemical_list: D000068258:Bevacizumab; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
keywords: angiogenesis; bevacizumab; breast cancer